title: Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1.
abstract: Excessive systemic inflammation following trauma, sepsis, or burn could lead to distant organ damage. The transplantation of bone marrow stromal cells or mesenchymal stem cells (MSCs) has been reported to be an effective treatment for several immune disorders by modulating the inflammatory response to injury. We hypothesized that MSCs can dynamically secrete systemic factors that can neutralize the activity of inflammatory cytokines. In this study, we showed that cocultured MSCs are able to decrease nuclear factor κ-B (NFκB) activation in target epithelial cells incubated in inflammatory serum conditions. Proteomic screening revealed a responsive secretion of soluble tumor necrosis factor (TNF) receptor 1 (sTNFR1) when MSCs were exposed to lipopolysaccharide (LPS)-stimulated rat serum. The responsive effect was eliminated when NFκB activation was blocked in MSCs. Intramuscular transplantation of MSCs in LPS-endotoxic rats decreased a panel of inflammatory cytokines and inflammatory infiltration of macrophages and neutrophils in lung, kidney, and liver when compared to controls. These results suggest that improvements of inflammatory responses in animal models after local transplantation of MSCs are at least, in part, explained by the NFκB-dependent secretion of sTNFR1 by MSCs.
authors.affiliation: Department of Surgery, Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, Massachusetts, USA.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yagi
authors.forename: Alejandro
authors.initials: A
authors.lastname: Soto-Gutierrez
authors.forename: Nalu
authors.initials: N
authors.lastname: Navarro-Alvarez
authors.forename: Yaakov
authors.initials: Y
authors.lastname: Nahmias
authors.forename: Yoni
authors.initials: Y
authors.lastname: Goldwasser
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Arno W
authors.initials: AW
authors.lastname: Tilles
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Tompkins
authors.forename: Biju
authors.initials: B
authors.lastname: Parekkadan
authors.forename: Martin L
authors.initials: ML
authors.lastname: Yarmush
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D002478:Cells, Cultured; D019446:Endotoxemia / Q000139:chemically induced / Q000378:metabolism / Q000628:therapy; D006801:Humans; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D059630:Mesenchymal Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D016328:NF-kappa B / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D018746:Systemic Inflammatory Response Syndrome / Q000139:chemically induced / Q000378:metabolism / Q000628:therapy*
chemical_list: D008070:Lipopolysaccharides; D016328:NF-kappa B; D047888:Receptors, Tumor Necrosis Factor, Type I